Aurobindo Pharma's Hyderabad-based biosimilars facility receives GMP certification from the European Medicines Agency, paving ...

CuraTeQ Biologics' EMA GMP certification marks a key milestone in Aurobindo Pharma's expansion into biosimilars, with three ...

Positive results from completed Phase 2 study of mavorixafor in chronic neutropenia (CN) announced todayPivotal Phase 3 trial of mavorixafor in ...

Neurizon Therapeutics Limited (Neurizon), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, announced it has received notice of a positive opinion from the European ...

Aurobindo Pharma subsidiary CuraTeQ Biologics has received a GMP certificate of compliance for its biosimilars manufacturing ...

Key strategic advancements include the ongoing review of nirogacestat by the European Medicines Agency and promising data from clinical trials for mirdametinib, indicating potential for future market ...

CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease treatment. - CBL-514 received both FDA Orphan Drug Designation and Fast Track designation for Dercum's ...

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a GMP certificate from the European Medicines Agency for its ...

There is no shortage of ASX healthcare companies with upcoming catalysts – a focal point for investors. ... Read More The ...

In the past decade, CPP has achieved significant success, including seven regulatory milestones, including the first ...

New Delhi, Nov 12 (PTI) Aurobindo Pharma on Tuesday said its unit has received GMP certificate of compliance for its Hyderabad-based biosimilars manufacturing facility from the European Medicines ...